Dr. Rosenberg on Immunotherapy in Non-Metastatic Muscle Invasive Bladder Cancer

Jonathan E. Rosenberg, MD
Published: Thursday, Aug 03, 2017



Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses immunotherapy in non-metastatic muscle-invasive bladder cancer.

Immunotherapy for this patient population is in an experimental stage, says Rosenberg.

Ongoing phase III trials are focusing on adjuvant therapy, which Rosenberg says patients who cannot receive platinum-based therapy after surgery should consider.
 


Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses immunotherapy in non-metastatic muscle-invasive bladder cancer.

Immunotherapy for this patient population is in an experimental stage, says Rosenberg.

Ongoing phase III trials are focusing on adjuvant therapy, which Rosenberg says patients who cannot receive platinum-based therapy after surgery should consider.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x